Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis

Clinical Nephrology

Volumn 71, Issue 3, 2009, Pages 286-295

  Hutchison, Alastair J ^a   Barnett, M E ^b   Krause, R ^c   Kwan, J T C ^d   Siami, G A ^e  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b Barnett Research and Communications   (United States)

^c KfH Nierenzentrum Moabit   (Germany)

^d ST HELIER HOSPITAL   (United Kingdom)

^e VANDERBILT UNIVERSITY   (United States)

Author keywords

Hemodialysis; Lanthanum carbonate; Liver; Phosphate binder

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALCIUM CARBONATE; GAMMA GLUTAMYLTRANSFERASE; LANTHANUM CARBONATE; LANTHANUM;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL LIVER DISEASE; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILE DUCT OBSTRUCTION; BILIARY TRACT PAIN; BILIRUBIN BLOOD LEVEL; BLOOD CLOTTING DISORDER; CHOLECYSTITIS; CHOLELITHIASIS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATTY LIVER; FOLLOW UP; GALLBLADDER DISEASE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMODIALYSIS; HEPATITIS; HEPATITIS C; HEPATOMEGALY; HEPATOSPLENOMEGALY; HUMAN; HYPERBILIRUBINEMIA; INCIDENCE; JAUNDICE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER HEMANGIOMA; LIVER TUMOR; LONG TERM CARE; MAJOR CLINICAL STUDY; PORPHYRIA; SIDE EFFECT; VIRUS HEPATITIS; CHRONIC KIDNEY FAILURE; DISEASE COURSE; DRUG EFFECT; ENZYMOLOGY; LIVER; META ANALYSIS; PATHOLOGY; RENAL REPLACEMENT THERAPY;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; DISEASE PROGRESSION; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; KIDNEY FAILURE, CHRONIC; LANTHANUM; LIVER; LIVER FUNCTION TESTS; RENAL DIALYSIS;

EID: 65549098263     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Adams PC. Is there a threshold of hepatic iron concentration that leads to cirrhosis in C282Y hemochromatosis? Am J Gastroenterol. 2001; 96: 567-569.
2. Ben-Dov IZ, Pappo O, Sklair-Levy M, Galitzer H, Ilan Y, Naveh-Many T, Silver J. Lanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic rats. Nephrol Dial Transplant. 2007; 22: 362-368.
3. Brewer GJ. Wilson disease and canine copper toxicosis. Am J Clin Nutr. 1998; 67: 1087S-1090S.
4. Britton RS. Metal-induced hepatotoxicity. Semin Liver Dis. 1996; 16: 3-12.
5. Damment SJP. Enlightenment on liver lanthanum exposure. Kidney Int. 2006; 70: 1372-1373.
6. Damment SJP, Pennick M. Systemic lanthanum is excreted in the bile of rats. Toxicol Lett. 2007; 171: 69-77.
7. Damment SJP, Greaves P, Downes N. The toxicology of lanthanum carbonate (Fosrenolρ), a new non-aluminum, non-calcium phosphate binder. J Am Soc Nephrol. 2003; 14: 204A.
8. Damment SJP, Secker R, Downes N. Lanthanum carbonate shows no adverse histopathological effects on liver in normal and uraemic rats. Nephrol Dial Transplant. 2006; 21: iv144-iv145.
9. D'Haese PC, Spasovski GB, Sikole A, Hutchison AJ, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, De Broe ME. Amulticenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int. 2003; Suppl: S73-78.
10. Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42: 1-201.
11. Finn WF. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol. 2006; 65: 191-202.
12. Finn WF, Joy MS. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis. Curr Med Res Opin. 2005; 21: 657-664.
13. Fuentealba I, Haywood S, Foster J. Cellular mechanisms of toxicity and tolerance in the copper-loaded rat. II. Pathogenesis of copper toxicity in the liver. Exp Mol Pathol. 1989; 50: 26-37.
14. Gross JB, Myers BM, Kost LJ, Kuntz SM, LaRusso NF. Biliary copper excretion by hepatocyte lysosomes in the rat. Major excretory pathway in experimental copper overload. J Clin Invest. 1989; 83: 30-39.
15. Hahm JS, Lee HL, Park JY, Eun CS, Han DS, Choi HS. Prevalence of gallstone disease in patients with end stage renal disease treated with hemodialysis in Korea. Hepatogastroenterology. 2003; 50: 1792-1795.
16. Haywood S. Copper toxicosis and tolerance in the rat. I - Changes in copper content of the liver and kidney. J Pathol. 1985; 145: 149-158.
17. Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, Backs W, Jamar R, Vosskuhler A. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract. 2005; 100: c8-19.
18. Hutchison AJ, D'Haese P, De Broe M. Lanthanum data in perspective. Kidney Int. 2006a; 70: 1382; author reply 1383.
19. Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, Backs W, Jamar R, Vosskuhler A. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract. 2006b; 102: c61-71.
20. Hutchison AJ, Barnett ME, Krause R, Kwan JTC, Siami GA, on behalf of the SPD405-309 Lanthanum Study Group. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract. 2008; 110: c15-c23.
21. Lacour B, Lucas A, AuchereD, Ruellan N, de Serre Patey NM, Drueke TB. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int. 2005; 67: 1062-1069.
22. LeSage GD, Kost LJ, Barham SS, LaRusso NF. Biliary excretion of iron from hepatocyte lysosomes in the rat. A major excretory pathway in experimental iron overload. J Clin Invest. 1986; 77: 90-97.
23. Maddrey WC. Drug-induced hepatotoxicity: 2005. J Clin Gastroenterol. 2005; 39: S83-89.
24. Park CH, Bacon BR, Brittenham GM, Tavill AS. Pathology of dietary carbonyl iron overload in rats. Lab Invest. 1987; 57: 555-563.
25. Pennick M, Dennis K, Damment SJ. Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. J Clin Pharmacol. 2006; 46: 738-746.
26. Salusky IB, Goodman WG, Sahney S, Gales B, Perilloux A, Wang HJ, Elashoff RM, Juppner H. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol. 2005; 16: 2501-2508.
27. Slatopolsky E, Liapis H, Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int. 2005; 68: 2809-2813.
28. Yang Z, Schryvers D, Roels F, D'Haese PC, De Broe ME. Demonstration of lanthanum in liver cells by energy dispersive X-ray spectroscopy, electron energy loss spectroscopy and high-resolution transmission electron microscopy. J Microsc. 2006; 223: 133-139.